Peptide derived bioavailable macrocycles as inhibitors of protein RNA and protei...
Peptide derived bioavailable macrocycles as inhibitors of protein RNA and protein protein interactions
The objective of this proposal is the elucidation of general principles for the design of bioavailable peptide-derived macrocyclic compounds and their use for the development of inhibitors of protein‒protein (PPI) and protein‒RNA...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SAF2009-08811
INTERFACES PROTEINA-PROTEINA: UN NUEVO TIPO DE DIANA TERAPEU...
145K€
Cerrado
RELOADPEPSYN
A Reloadable Molecular Peptide Synthesizer
231K€
Cerrado
GLYCOPEPTIDES
Solid phase synthesis biophysical study and biological eva...
175K€
Cerrado
BES-2017-080618
ESTUDIOS SOBRE RECONOCIMIENTO MOLECULAR DE GLICOSIDOS: BASES...
93K€
Cerrado
DOS
Drugging the Undruggable Discovery of Protein Protein Inter...
1M€
Cerrado
CTQ2015-70698-R
SISTEMAS SUPRAMOLECULARES PARA RECONOCIMIENTO BIOMOLECULAR:...
121K€
Cerrado
Información proyecto PEP-PRO-RNA
Duración del proyecto: 66 meses
Fecha Inicio: 2016-02-25
Fecha Fin: 2021-08-31
Líder del proyecto
STICHTING VU
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
1M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The objective of this proposal is the elucidation of general principles for the design of bioavailable peptide-derived macrocyclic compounds and their use for the development of inhibitors of protein‒protein (PPI) and protein‒RNA interactions (PRI). Over the last decade, drug discovery faced the problem of decreasing success rates which is mainly caused by the fact that numerous novel biological targets are reluctant to classic small molecule modulation. In particular, that holds true for PPIs and PRIs. Approaches that allow the modulation of these interactions provide access to therapeutic agents targeting crucial biological processes that have been considered undruggable so far. Herein, I propose the use of irregularly structured peptide binding epitopes as starting point for the design of bioactive macrocycles. In a two-step process high target affinity and bioavailability are installed:
1) Peptide macrocyclization for the stabilization of the irregular bioactive secondary structure
2) Evolution of the cyclic peptide into a bioavailable macrocyclic compound
Using a well-characterized model system developed in my lab, initial design principles will be elucidated. These principles are subsequently used and refined for the development of macrocyclic PPI and PRI inhibitors. The protein‒protein and protein‒RNA complexes selected as targets are of therapeutic interest and corresponding inhibitors hold the potential to be pursued in subsequent drug discovery campaigns.